作为一个疫苗生产大国,我国疫苗产业坐拥10亿元规模的年出口能力,但却因自主创新能力弱、技术水平不高、产品同质化等缺陷,面临着严重的产能过剩问题。目前全国有40家疫苗企业,仅仅是流感疫苗就有15家企业在生产。其中重要原因之一就是细胞株种类匮乏,作为疫苗重要原料之一的细胞株虽然有上千个种类,但我国疫苗生产企业近20年来常用的仅有10种左右。日前,随着一种新的细胞株EB66的引入,这一困境或许有望得到彻底改变。3月14日,甘肃健顺生物科技有限公司(以下简称“健顺生物”)与法国Valneva公司EB66细胞株合作项 As a large vaccine producer, the vaccine industry in our country has an annual export capacity of 1 billion yuan. However, due to its weak capability of independent innovation, low level of technology and product homogeneity, it faces a serious problem of overcapacity. There are currently 40 vaccine companies nationwide, with 15 companies producing influenza alone. One of the important reasons is the lack of cell lines, as one of the important vaccine ingredients of cell lines, although there are thousands of species, but our vaccine manufacturers in the past 20 years, only about 10 commonly used. Recently, with the introduction of a new cell line EB66, this dilemma may be expected to be completely changed. March 14, Gansu Jianshun Biological Technology Co., Ltd. (hereinafter referred to as “Jianshun biological”) and France Valneva company EB66 cell line cooperation